Tuesday, March 17, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Talking DPC with Miss Tiffany Ryder

We speak with Miss Tiffany Ryder about her experiences treating patients in rural emergency departments and her thoughts on future trends in direct primary care.

Tiffany Ryder is an NFL Cheerleader turned Emergency Medicine PA and is passionate about facilitating access to affordable primary care. She is a founding partner of Direct Care Connect, a non-profit healthcare delivery model with a vision to provide direct primary care services to underserved and uninsured communities in the US. She writes and speaks frequently on her personal and clinical experiences highlighting the need for expanded access to patient education and services in these populations.

To learn more about her work, select the following link: https://www.tiffanyryder.com/

#tiffanyryder #direct #primary #care #concierge #medicine

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

Policy Shift in Peptide Regulation

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!